FDA to review controversial peptides promoted by RFK Jr.

US regulators are set to scrutinize a group of seven peptides, compounds increasingly marketed as wellness treatments, as demand for them surges. The US Food and Drug Administration's Pharmacy Compounding Advisory Committee will meet to decide if these substances can be made available through licensed pharmacies with prescriptions.

Peptides, short chains of amino acids, occur naturally in the body. While some peptide-based medicines like GLP-1 weight-loss drugs have gained widespread recognition, the seven compounds under review, including BPC-157, TB-500, and KPV, are promoted for a broad range of conditions. These include ulcerative colitis, wound healing, inflammatory conditions, obesity, migraines, chronic pain, insomnia, and opioid withdrawal.

The trend has been amplified by social media influencers, the "looksmaxxing" beauty trend, and endorsements from Health Secretary Robert F. Kennedy Jr., who has spoken positively about his own use of peptides. However, FDA scientists have repeatedly raised concerns, citing inadequate human clinical trials and issues with quality, stability, and consistency. Despite these reservations, demand continues to grow, with compounds marketed through wellness clinics and online forums where users share experiences and discuss suppliers.

Industry groups argue that the high demand justifies making the compounds more accessible. The FDA's review highlights a growing tension between the burgeoning wellness market for peptides and regulatory concerns about scientific evidence and public safety.